Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab plus best supportive care in pediatric HSCT-associated thrombotic microangiopathy
jRCT2071200070Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in thrombotic microangiopathies (TMA), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA Response. Started Dec 2020; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on jRCT2071200070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200070.